Product Information
BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB is a generic product labeled by Viona Pharmaceuticals Inc., priced at $0.2203 per EA under NDC 72578011405. Its NADAC has been published 117 times since Jul 10, 2024.
FDA first approved this application on Nov 4, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB
bisoprolol fumarate and hydrochlorothiazideStrength
5; 6.25 mg/1; mg/1
Manufacturer
Viona Pharmaceuticals Inc.NDC
72578011405
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215666FDA Approved
11/4/2022
TE Code
AB
On Market Since
3/1/2023
Pharmacological Classes
Price Statistics
The NADAC for BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB has been published 117 times since Jul 10, 2024, and over the history we have for it it has declined 12.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2203 per EA |
|---|---|
| All-time high | $0.2522 (Jul 10, 2024) |
| All-time low | $0.1467 (Nov 20, 2024) |
| 52-week high | $0.2203 |
| 52-week low | $0.1916 |
| Median price | $0.2077 |
| Average price | $0.2041 |
| Largest weekly change | -32.1% (Nov 20, 2024) |
| Weeks tracked | 117 |
| Tracking since | Jul 10, 2024 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Viona Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bisoprolol fumarate and hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Thiazide Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB, manufactured by Viona Pharmaceuticals Inc., is $0.2203 per EA (NDC 72578011405), effective Sep 30, 2026.
How has the price of BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB changed over time?
Over the history we have for it, the NADAC for BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB has declined 12.7%. It has been tracked across 117 weekly CMS publications since Jul 10, 2024.
What are the highest and lowest recorded NADAC prices for BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB?
Since Jul 10, 2024, the NADAC for BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB has ranged from a low of $0.1467 (Nov 20, 2024) to a high of $0.2522 (Jul 10, 2024), with a median of $0.2077 per EA.
Are there cheaper alternatives to BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB?
BISOPROLOL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB (NDC 72578011405) is labeled by Viona Pharmaceuticals Inc., and CMS classifies it as a generic product.